Topical administration of nanocarrier miRNA‐210 antisense ameliorates imiquimod‐induced psoriasis‐like dermatitis in mice

Feng, Huan; Wu, Ruifang; Zhang, Suhan; Kong, Yi Wen; Liu, Zixin; Wu, Haijing; Wang, Honglin; Y, Su; Zhao, Ming; Lu, Qianjin

doi:10.1111/1346-8138.15149

Cited by 34 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intriguingly, a recent study developed nanocarrier gel containing miR-210 antisense (NG-anti-miR-210) to topically inhibit miR-210 expression in the imiquimod-induced mouse model of psoriasis. The results showed that inhibition of miR-210 significantly alleviates psoriasis-like inflammation in mice with a decreased proportion of Th1 and Th17 cells in dermal and splenic cells, which paves the way for RNA drug development for psoriasis (67). miR-138 is significantly downregulated in CD4 + T cells from psoriasis patients (11,55).…”

Section: Mirnas Work In Concert To Distort Cd4 + T Cell Subsets Balancementioning

confidence: 91%

miRNAs Flowing Up and Down: The Concerto of Psoriasis

Yang

Wang

2021

Front. Med.

View full text Add to dashboard Cite

Psoriasis is a chronic immune-mediated skin disease, whose hallmarks include keratinocyte hyperproliferation and CD4+ T cell subsets imbalance. Dysregulated microRNAs (miRNAs) identified in psoriasis have been shown to affect keratinocyte and T cell functions, with studies on the molecular mechanisms and intrinsic relationships of the miRNAs on the way. Here, we focus on the dysregulated miRNAs that contribute to the two hallmarks of psoriasis with the miRNA target genes confirmed. We review a network, in which, upregulated miR-31/miR-203/miR-155/miR-21 and downregulated miR-99a/miR-125b facilitate the excessive proliferation and abnormal differentiation of psoriatic keratinocytes; upregulated miR-210 and downregulated miR-138 work in concert to distort CD4+ T cell subsets balance in psoriasis. The miRNAs exert their functions through regulating key psoriasis-associated transcription factors including NF-κB and STAT3. Whether flowing up or down, these miRNAs collaborate to promote the development and maintenance of psoriasis.

show abstract

Section: Mirnas Work In Concert To Distort Cd4 + T Cell Subsets Balancementioning

confidence: 91%

miRNAs Flowing Up and Down: The Concerto of Psoriasis

Yang

Wang

2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…The expression of miR‐210 was enhanced by TGF‐β and IL‐23 by inducing HIF‐1α responsible for histone H3 acetylation in the miR‐210 promoter region. This study suggested that inhibition of miR‐210 effectively reduces psoriasis‐like inflammation and can be a potential therapeutic approach 18,19 …”

Section: Mirna In Psoriasismentioning

confidence: 86%

“…In addition, there was improved erythema, scales, acanthosis, and dermal inflammatory cell infiltration. There was a decrease in interleukin‐17A, c‐interferon mRNA levels, and proportion of T‐helper 1 (Th‐1) and Th‐17 cells in dermal and splenic cells 18 . The miR‐210 found to inhibit Th2 differentiation by suppressing STAT6 and LYN expression leading to an immune imbalance in psoriasis development.…”

Section: Mirna In Psoriasismentioning

confidence: 99%

Insightful exploring of microRNAs in psoriasis and its targeted topical delivery

Pradyuth

Rapalli

Gorantla

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Psoriasis is a common immune-mediated inflammatory skin disease. It includes multifaceted interaction between the immune system and the keratinocytes. Recent studies depicted the role of microRNAs (miRNAs) in hyperproliferation of keratinocytes and inflammatory cytokine production, which serve as biomarkers for diagnosis, monitoring treatment response, and prognosis. miRNAs are small nucleotide sequenced noncoding RNAs. Deregulation of miRNAs was found to be the most common factor in the studies pertaining to psoriasis. Hence, miRNA-based targeting for psoriasis treatment became the primary field of current research. miRNA due to its spatial and chemical properties offer different challenges in the process of its delivery. The topical delivery of different siRNAs and genes has paved a way to similar delivery of miRNA. The topical delivery of miRNAs to the skin can bring a revolutionary change in the field of psoriasis treatment.

show abstract

“…After Feng et al (28) demonstrated in a previous study the involvement of microRNAs (miRNAs/miRs) in the pathogenesis of psoriasis, an anti-psoriasis effect was obtained after topical administration of antisense miRNA-210 in a reconstituted high-density lipoprotein nano-transporter gel.…”

Section: Summary and Discussion Of The New Topical Treatment Strategiesmentioning

confidence: 99%

Experimental research in topical psoriasis therapy (Review)

et al. 2021

View full text Add to dashboard Cite

Psoriasis, one of the most prevalent inflammatory diseases in dermatologic pathology, remains a challenge in regards to the therapeutic approach. Topical therapy for psoriasis is a current trending subject as it implies good compliance for the patient, few adverse systemic reactions and a targeted effect. Numerous substances are now being tested, from natural to synthetic compounds and already known substances in improved formulas such as vesicular systems. The aim of this article was to conduct a literature review regarding the topical therapy of psoriasis in animal models, between June, 27, 2019 and July 9, 2020. For this article, the authors conducted extensive research in PubMed with the following keywords: Psoriasis AND (topical OR local) and (therapy OR treatment) AND (mice OR rats). The main new studied substances included lycopene, sodium butyrate, salvianolic acid B, small interfering RNAs (siRNAs) in ionic liquids, albendazole, phosphodiesterase inhibitors, biomimetic reconstituted highdensity lipoprotein nanocarrier gel containing microRNA (miRNA)-210 antisense, thymoquinone in ethosomal vesicle, Sea buckthorn oil (Hippophae rhamnoides), nitidine chloride, Melissa officinalis spp. Altissima extract and [1-(4-chloro-3nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (CIM). New formulas of already known anti-psoriasis substances such as: Cyclosporine, methotrexate, calcipotriol, tazarotene, protein kinase p38 and integrin α5β1 as a target, are also reviewed. Recent research in topical psoriasis underlines the importance of animal experimental research in dermatology, providing a starting point for developing new therapeutic approaches in one of the most frequently diagnosed chronic dermatologic diseases. Vesicular systems are now providing the best vehicle for topical therapy, thus easing the action of the active substances at their target sites. Contents 1. Introduction 2. Research methods 3. Summary and discussion of the new topical treatment strategies 4. Discussion 5. Conclusions

show abstract

Topical administration of nanocarrier miRNA‐210 antisense ameliorates imiquimod‐induced psoriasis‐like dermatitis in mice

Cited by 34 publications

References 27 publications

miRNAs Flowing Up and Down: The Concerto of Psoriasis

miRNAs Flowing Up and Down: The Concerto of Psoriasis

Insightful exploring of microRNAs in psoriasis and its targeted topical delivery

Experimental research in topical psoriasis therapy (Review)

Contact Info

Product

Resources

About